Tremblay G1, Tomaras D2, Mearns ES3, Copher R3
1Purple Squirrel Economics, New York, NY, USA, 2Purple Squirrel Economics, Montreal, QC, Canada, 3Bristol-Myers Squibb, Summit, NJ, USA

OBJECTIVES: To establish a conceptual framework to aid in the economic evaluation of the treatment of beta-thalassemia (BT) to assess cost-effectiveness, long-term effects, and resource use.

METHODS: An economic conceptual framework was developed from a US payer perspective using literature and clinical rationale. Efficacy and safety outcomes, health states, technical assumptions, economic endpoints, and costs were considered. Key value drivers were identified to help optimize future economic models. Different sets of assumptions were considered and tested using a Markov model. The model framework and clinical rationale were validated by expert hematologists.

RESULTS: A lifetime horizon was modeled because patients with BT often require lifelong red blood cell transfusions (RBCTs). In addition to disease pathology, RBCTs lead to iron loading and contribute to significant morbidity (e.g. increased long-term complications, complication costs, reduced quality of life) and early mortality. A lifetime horizon further permitted the use of age-related increases for complication rates and captured the long-term outcomes of key therapies (curative or otherwise). Six health states were modeled to capture the patient lifetime journey: transfusion-independence, low transfusion burden, medium transfusion burden, high transfusion burden, treatment discontinuation, and mortality. These health states enabled the inclusion of response status defined in terms of transfusion burden and treatment discontinuation. The cost of iron chelation therapy was a key driver across health states, increasing costs with greater transfusion burden. Drug costs, routine care, complication(s), adverse events, mortality, and indirect costs were also key drivers. This conceptual model framework permitted the reporting of results in incremental costs per QALY, LY, and responder.

CONCLUSIONS: This conceptual framework can be used to perform future economic evaluations of the treatment of BT, to capture long-term effects, complications, and mortality, and to provide researchers and policymakers with the appropriate tools for informed decision-making.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Value in Health, Volume 23, Issue 5, S1 (May 2020)




Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis


Systemic Disorders/Conditions

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now